GSK plc (GSK) advanced 1.72% after reporting strong Q3 earnings growth and reaffirming its 2026 guidance, capturing renewed buying interest. The move is supported by the stock sustaining prices above its 20-day and 50-day moving averages, but limited by overhead resistance near the 200-day moving average at GBX1,954.
Highlights
- GSK delivered 5% sales growth in the third quarter, with year-to-date operating cash flow up £1.1 billion to £7.4 billion.
- The company raised free cash flow by £1.8 billion and declared a third-quarter dividend of 17 pence per share, reaffirming 2026 guidance.
- Shares of GSK trade with strong short- and medium-term bullish momentum, with a projected 5-day range of GBX1,914 to GBX1,981 and high probability of further gains if resistance at GBX1,954 is surpassed.
Operating cash flow and dividend grow as 2026 guidance holds
GSK reported strong third-quarter earnings, highlighted by 5% sales growth and robust cash generation. Year-to-date operating cash flow reached £7.4 billion, £1.1 billion above the prior year, while free cash flow increased by £1.8 billion. The company also declared a third-quarter dividend of 17 pence per share and reaffirmed its 2026 guidance, with management addressing segment pressures and pipeline development.
Bullish signals persist with price capped below key moving average
GSK is trading above its 20-day and 50-day moving averages at GBX1,878 and GBX1,846, indicating continued bullish momentum in the short and medium term. The price remains just below the 200-day moving average at GBX1,954, which serves as the main resistance level, with immediate support at the week high of GBX1,944. Momentum indicators are positive, with the MACD and Awesome Oscillator both signaling ongoing buying interest, and the Average Directional Index (ADX) pointing to a neutral trend. All three oscillators—Relative Strength Index (RSI), Stochastic RSI, and Commodity Channel Index (CCI)—are in neutral ranges. Bull/Bear Power (BBP) is positive, supporting the dominance of buyers in recent trading.
Earlier, analysts noted that GSK's technical setup and improving cash flow positioned the stock for possible movement if it could surpass key resistance. The current price action reinforces this scenario, with a decisive close above GBX1,954 now serving as the primary level to watch for confirmation of further upside potential.